{"id":"intravenous-cisplatin-etoposide","safety":{"commonSideEffects":[{"rate":"60-90","effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":"70-90","effect":"Nausea and vomiting"},{"rate":"60-80","effect":"Alopecia"},{"rate":"30-50","effect":"Mucositis"},{"rate":"20-40","effect":"Nephrotoxicity"},{"rate":"10-30","effect":"Ototoxicity"},{"rate":"10-20","effect":"Peripheral neuropathy"},{"rate":"1-5","effect":"Secondary malignancy (long-term)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cisplatin is a platinum-based alkylating agent that forms DNA cross-links, preventing DNA replication and transcription. Etoposide is a topoisomerase II inhibitor that prevents DNA strand rejoining after breakage. The combination exploits complementary mechanisms to maximize cytotoxic effects against rapidly dividing cancer cells.","oneSentence":"Cisplatin and etoposide are chemotherapy agents that work together to damage cancer cell DNA and prevent cell division, leading to cancer cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:48.346Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Small cell lung cancer"},{"name":"Germ cell tumors"},{"name":"Lymphomas"},{"name":"Other solid tumors (indication-dependent based on trial design)"}]},"trialDetails":[{"nctId":"NCT06897579","phase":"PHASE2","title":"Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-07","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":134},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":"Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT02114229","phase":"PHASE2","title":"Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2014-05-14","conditions":"Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor","enrollment":125},{"nctId":"NCT06157827","phase":"PHASE1, PHASE2","title":"A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma","status":"RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2023-12-08","conditions":"Advanced Neuroendocrine Carcinoma","enrollment":178},{"nctId":"NCT04486391","phase":"PHASE3","title":"Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma","status":"TERMINATED","sponsor":"BeiGene","startDate":"2020-12-14","conditions":"Classical Hodgkin Lymphoma","enrollment":3},{"nctId":"NCT06942039","phase":"EARLY_PHASE1","title":"Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation","status":"RECRUITING","sponsor":"C17 Council","startDate":"2025-09-23","conditions":"CNS Embryonal Tumor, CNS, Medulloblastoma, Atypical Teratoid Rhabdoid Tumor","enrollment":15},{"nctId":"NCT05403723","phase":"PHASE1","title":"Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC","status":"SUSPENDED","sponsor":"University of Maryland, Baltimore","startDate":"2026-06-30","conditions":"Extensive-stage Small-cell Lung Cancer","enrollment":50},{"nctId":"NCT06712355","phase":"PHASE3","title":"Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-02-03","conditions":"Extensive-stage Small-cell Lung Cancer","enrollment":621},{"nctId":"NCT06230224","phase":"PHASE3","title":"A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-02-15","conditions":"B-Cell Non-Hodgkin Lymphoma (B-NHL)","enrollment":216},{"nctId":"NCT07381543","phase":"PHASE2","title":"Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2026-03","conditions":"Localized Small Cell Lung Cancer","enrollment":76},{"nctId":"NCT07381829","phase":"PHASE1","title":"A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer","status":"RECRUITING","sponsor":"HC Biopharma Inc.","startDate":"2025-10-27","conditions":"Advanced Solid Tumor Cancer","enrollment":328},{"nctId":"NCT06564844","phase":"PHASE3","title":"A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-10-15","conditions":"Non-small Cell Lung Cancer","enrollment":24},{"nctId":"NCT00602667","phase":"PHASE2","title":"Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2007-12-17","conditions":"Brain and Central Nervous System Tumors","enrollment":293},{"nctId":"NCT06741644","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"CStone Pharmaceuticals","startDate":"2025-02-24","conditions":"Advanced Solid Tumors","enrollment":660},{"nctId":"NCT06077500","phase":"PHASE1","title":"DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2024-02-14","conditions":"Small Cell Lung Carcinoma (SCLC)","enrollment":45},{"nctId":"NCT06132113","phase":"PHASE1","title":"DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2024-01-22","conditions":"Neuroendocrine Neoplasms","enrollment":55},{"nctId":"NCT03519971","phase":"PHASE3","title":"Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-03-29","conditions":"Non-Small Cell Lung Cancer","enrollment":328},{"nctId":"NCT02964013","phase":"PHASE1","title":"Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-12-13","conditions":"Neoplasms","enrollment":474},{"nctId":"NCT07187960","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.","startDate":"2025-11","conditions":"Follicular Lymphoma","enrollment":228},{"nctId":"NCT07155122","phase":"PHASE2","title":"Efficacy and Safety of Serplulimab Combined With Etoposide and Cisplatin as Neoadjuvant Therapy in Limited-Stage Small-Cell Carcinoma of the Esophageal","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-09-01","conditions":"Small-Cell Carcinoma of the Esophageal","enrollment":15},{"nctId":"NCT05796089","phase":"PHASE2","title":"Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Trans Tasman Radiation Oncology Group","startDate":"2022-01-01","conditions":"Extensive-Stage Small-Cell Lung Cancer","enrollment":35},{"nctId":"NCT04047862","phase":"PHASE1","title":"Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors","status":"COMPLETED","sponsor":"BeiGene","startDate":"2019-08-15","conditions":"Locally Advanced and Metastatic Solid Tumors","enrollment":446},{"nctId":"NCT07138001","phase":"PHASE2","title":"Phase 2 Clinical Trial of KH617","status":"NOT_YET_RECRUITING","sponsor":"Sichuan Honghe Biotechnology Co., Ltd.","startDate":"2025-08","conditions":"Recurrent Glioblastoma","enrollment":60},{"nctId":"NCT04380636","phase":"PHASE3","title":"Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-06","conditions":"Lung Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":870},{"nctId":"NCT05298423","phase":"PHASE3","title":"Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-05-03","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":611},{"nctId":"NCT07091305","phase":"PHASE2","title":"A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2025-07-01","conditions":"Limited-stage Small Cell Lung Cancer (LS-SCLC), Chemoradiotherapy, Induction Therapy","enrollment":28},{"nctId":"NCT05224141","phase":"PHASE3","title":"Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-03-24","conditions":"Small Cell Lung Carcinoma","enrollment":460},{"nctId":"NCT04624204","phase":"PHASE3","title":"Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-12-08","conditions":"Small Cell Lung Cancer","enrollment":672},{"nctId":"NCT05312671","phase":"PHASE2","title":"Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2022-06-27","conditions":"Small Cell Neuroendocrine Carcinoma of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder","enrollment":63},{"nctId":"NCT04905316","phase":"PHASE2","title":"A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-05-21","conditions":"Non-small Cell Lung Cancer","enrollment":41},{"nctId":"NCT04774380","phase":"PHASE3","title":"Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-11-11","conditions":"Extensive-stage Small Cell Lung Cancer","enrollment":152},{"nctId":"NCT04668365","phase":"PHASE2","title":"Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma","status":"SUSPENDED","sponsor":"Henan Cancer Hospital","startDate":"2020-12-25","conditions":"Diffuse Large B Cell Lymphoma, CD79A Gene Mutation, CD79B Gene Mutation","enrollment":59},{"nctId":"NCT05384015","phase":"PHASE2","title":"Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Fundación GECP","startDate":"2022-11-07","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":46},{"nctId":"NCT06869239","phase":"","title":"Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-02-25","conditions":"Limited-stage Small Cell Lung Cancer (LS-SCLC)","enrollment":65},{"nctId":"NCT03509012","phase":"PHASE1","title":"Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-05-02","conditions":"Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma","enrollment":105},{"nctId":"NCT06480864","phase":"NA","title":"Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Yunpeng Liu","startDate":"2024-08-09","conditions":"Small Cell Lung Cancer","enrollment":38},{"nctId":"NCT02794571","phase":"PHASE1","title":"Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2016-05-23","conditions":"Advanced/Metastatic Tumors","enrollment":518},{"nctId":"NCT06649448","phase":"NA","title":"A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy.","status":"NOT_YET_RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2024-10-10","conditions":"Solid Tumor Cancer, Chemotherapy Induced Neutropenia, G-CSF","enrollment":200},{"nctId":"NCT03850067","phase":"PHASE1","title":"A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Celgene","startDate":"2019-03-12","conditions":"Small Cell Lung Carcinoma","enrollment":90},{"nctId":"NCT06536868","phase":"PHASE2","title":"Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC","status":"RECRUITING","sponsor":"Second Hospital of Shanxi Medical University","startDate":"2024-08-01","conditions":"Extensive-stage Small-cell Lung Cancer","enrollment":40},{"nctId":"NCT04622228","phase":"PHASE2","title":"Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-12-16","conditions":"Carcinoma, Small Cell Lung","enrollment":56},{"nctId":"NCT06489808","phase":"PHASE2","title":"Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-05-28","conditions":"Relapsed/Refractory Large B-Cell Lymphoma","enrollment":89},{"nctId":"NCT06485544","phase":"PHASE2","title":"Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial","status":"RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2024-07-01","conditions":"Small Cell Lung Cancer (SCLC)","enrollment":104},{"nctId":"NCT04562337","phase":"PHASE2","title":"SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in ES-SCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2020-10-01","conditions":"Extensive-stage Small Cell Lung Cancer","enrollment":67},{"nctId":"NCT06477523","phase":"PHASE1, PHASE2","title":"Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2024-05-16","conditions":"SCLC, Extensive Stage","enrollment":57},{"nctId":"NCT06478264","phase":"PHASE2","title":"A Study of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Zhangzhou Municipal Hospital","startDate":"2024-07-13","conditions":"Esophageal Small Cell Carcinoma","enrollment":40},{"nctId":"NCT05765825","phase":"PHASE2","title":"Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2023-03-07","conditions":"Extensive-stage Small-cell Lung Cancer","enrollment":61},{"nctId":"NCT06371482","phase":"PHASE2","title":"Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2023-06-01","conditions":"SCLC, Limited Stage","enrollment":58},{"nctId":"NCT06372626","phase":"PHASE1, PHASE2","title":"Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.","status":"RECRUITING","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2024-05-30","conditions":"Neuroendocrine Carcinoma","enrollment":93},{"nctId":"NCT06441344","phase":"PHASE3","title":"Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell","status":"NOT_YET_RECRUITING","sponsor":"Taizhou Hospital","startDate":"2024-07-01","conditions":"SCLC, Maintenance Treatment","enrollment":136},{"nctId":"NCT06217757","phase":"PHASE1, PHASE2","title":"Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2024-04-18","conditions":"Lung Cancer, Extensive-stage Small-cell Lung Cancer","enrollment":45},{"nctId":"NCT06375109","phase":"PHASE2","title":"PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC","status":"NOT_YET_RECRUITING","sponsor":"Beijing Chest Hospital, Capital Medical University","startDate":"2024-04-16","conditions":"Limited-stage Small-cell Lung Cancer","enrollment":60},{"nctId":"NCT03840902","phase":"PHASE2","title":"M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)","status":"TERMINATED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2019-04-16","conditions":"Non-small Cell Lung Cancer","enrollment":153},{"nctId":"NCT05092412","phase":"PHASE2","title":"Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC","status":"UNKNOWN","sponsor":"You Lu","startDate":"2022-03-02","conditions":"Lung Cancer, Extensive-stage Small-cell Lung Cancer, Durvalumab","enrollment":30},{"nctId":"NCT06177925","phase":"PHASE2","title":"A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2023-12-10","conditions":"Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site","enrollment":62},{"nctId":"NCT02580994","phase":"PHASE2","title":"Pembrolizumab in Untreated Extensive SCLC","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2017-12-08","conditions":"Small Cell Lung Cancer (SCLC)","enrollment":125},{"nctId":"NCT06102746","phase":"","title":"Clinical Study of Surufatinib Plus Sintilimab Combined With Chemotherapy in the Treatment of Advanced Gastric Neuroendocrine Carcinoma","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-04-10","conditions":"Gastric Neuroendocrine Carcinoma","enrollment":20},{"nctId":"NCT03568097","phase":"PHASE2","title":"Immunotherapy in Combination With Chemotherapy in Small-cell Lung Cancer","status":"UNKNOWN","sponsor":"Hellenic Cooperative Oncology Group","startDate":"2018-09-16","conditions":"Small Cell Lung Carcinoma","enrollment":55},{"nctId":"NCT05873790","phase":"","title":"Minimal Residual Disease Dynamic Monitoring in First-Line Serplulimab Plus Chemotherapy in Treatment of Extensive Small Cell Lung Cancer: An Observational Study","status":"UNKNOWN","sponsor":"The First Hospital of Jilin University","startDate":"2023-06-01","conditions":"Lung Cancer","enrollment":30},{"nctId":"NCT05668767","phase":"PHASE2","title":"Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC","status":"UNKNOWN","sponsor":"Beijing Chest Hospital","startDate":"2022-12","conditions":"Extensive-stage Small-cell Lung Cancer","enrollment":20},{"nctId":"NCT02937116","phase":"PHASE1","title":"First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2016-10-19","conditions":"Cancer, Solid Tumor","enrollment":233},{"nctId":"NCT05484583","phase":"PHASE2","title":"Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases","status":"NOT_YET_RECRUITING","sponsor":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","startDate":"2022-08-01","conditions":"Lung Cancer, Extensive-stage Small-cell Lung Cancer, Radiotherapy","enrollment":58},{"nctId":"NCT05245994","phase":"PHASE2","title":"An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese","status":"UNKNOWN","sponsor":"Li Zhang, MD","startDate":"2021-08-21","conditions":"Lung Cancer, Small Cell Lung Cancer, Durvalumab","enrollment":60},{"nctId":"NCT05142865","phase":"PHASE2","title":"Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine Carcinomas","status":"UNKNOWN","sponsor":"Huazhong University of Science and Technology","startDate":"2022-01-14","conditions":"Advanced or Metastatic EP-NEC","enrollment":30},{"nctId":"NCT05076786","phase":"PHASE2","title":"Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-10-27","conditions":"Neuroendocrine Tumors, Neuroendocrine Carcinoma","enrollment":28},{"nctId":"NCT04982549","phase":"PHASE2","title":"A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC","status":"UNKNOWN","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2021-01-21","conditions":"Unresectable Stage III NSCLC","enrollment":35},{"nctId":"NCT01840579","phase":"PHASE1","title":"Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-04-26","conditions":"Solid Tumor, Non-small Cell Lung Cancer, Small Cell Lung Cancer","enrollment":57},{"nctId":"NCT03901378","phase":"PHASE2","title":"Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma","status":"WITHDRAWN","sponsor":"Ochsner Health System","startDate":"2019-10-02","conditions":"Neuroendocrine Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, High Grade Neuroendocrine Carcinoma, Any Site","enrollment":""},{"nctId":"NCT03116971","phase":"PHASE1","title":"Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)","status":"TERMINATED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2017-05-25","conditions":"Small Cell Lung Cancer","enrollment":2},{"nctId":"NCT00514540","phase":"PHASE2","title":"Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-05","conditions":"Prostate Cancer","enrollment":121},{"nctId":"NCT03745222","phase":"PHASE3","title":"A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"Celgene","startDate":"2019-05-22","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":1},{"nctId":"NCT01450761","phase":"PHASE3","title":"Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-12-13","conditions":"Small Cell Lung Carcinoma","enrollment":1351},{"nctId":"NCT02786719","phase":"NA","title":"High-Risk Neuroblastoma Chemotherapy Without G-CSF","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2016-06","conditions":"Neuroblastoma","enrollment":13},{"nctId":"NCT00537511","phase":"PHASE1, PHASE2","title":"A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide","status":"TERMINATED","sponsor":"Celgene","startDate":"2008-02-01","conditions":"Carcinoma, Small Cell","enrollment":22},{"nctId":"NCT04065308","phase":"PHASE2","title":"Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2019-01-14","conditions":"Multiple Myeloma in Relapse, Plasmacytoma, Daratumumab","enrollment":33},{"nctId":"NCT01822496","phase":"PHASE2","title":"Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2013-11-04","conditions":"Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7","enrollment":59},{"nctId":"NCT00554463","phase":"PHASE2","title":"G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2008-01","conditions":"Lung Cancer","enrollment":5},{"nctId":"NCT00031590","phase":"PHASE2","title":"Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly Diagnosed Medulloblastoma","status":"TERMINATED","sponsor":"Children's Hospital of Philadelphia","startDate":"2001-04","conditions":"Brain Tumors, Central Nervous System Tumors, Medulloblastoma","enrollment":30},{"nctId":"NCT02243436","phase":"PHASE1, PHASE2","title":"Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","startDate":"2014-11-11","conditions":"CLASSICAL HODGKIN LYMPHOMA","enrollment":67},{"nctId":"NCT00924209","phase":"PHASE2","title":"A Phase II Study of Neo-Adjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA (N2) Non-Squamous Cell Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-03","conditions":"NSCLC, Stage IIIA (N2)","enrollment":7},{"nctId":"NCT01453205","phase":"PHASE2","title":"A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2012-02-27","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":187},{"nctId":"NCT00577512","phase":"PHASE2","title":"2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2007-04","conditions":"Multiple Myeloma","enrollment":4},{"nctId":"NCT00113919","phase":"PHASE1, PHASE2","title":"UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients","status":"TERMINATED","sponsor":"University of Arkansas","startDate":"2004-06","conditions":"Multiple Myeloma","enrollment":14},{"nctId":"NCT00320359","phase":"PHASE3","title":"Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung Cancer","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-08","conditions":"Lung Cancer, Small Cell","enrollment":700},{"nctId":"NCT02883543","phase":"PHASE3","title":"First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation","status":"UNKNOWN","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2016-06","conditions":"Non-small Cell Lung Cancer","enrollment":330},{"nctId":"NCT00686959","phase":"PHASE3","title":"Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-09","conditions":"Non Small Cell Lung Cancer","enrollment":598},{"nctId":"NCT01745445","phase":"PHASE2","title":"Clinical Randomized Study of Concurrent Chemo-radiotherapy vs Radiotherapy Alone to Local-advanced Small Cell Lung Cancer (SCLC)","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2012-01","conditions":"Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT00083551","phase":"PHASE3","title":"UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"1998-08","conditions":"Multiple Myeloma","enrollment":668},{"nctId":"NCT00391586","phase":"PHASE2","title":"Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung","status":"TERMINATED","sponsor":"New Mexico Cancer Research Alliance","startDate":"2006-07","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":45},{"nctId":"NCT00658580","phase":"PHASE3","title":"Randomized Study of Cisplatin-Etoposide Versus an Etoposide Regimen Without Cisplatin in Extensive Small-Cell Lung Cancer","status":"COMPLETED","sponsor":"European Lung Cancer Working Party","startDate":"2000-04","conditions":"Small Cell Lung Carcinoma, Extensive Disease","enrollment":361},{"nctId":"NCT01947062","phase":"PHASE3","title":"Metronomic Cyclophosphamide in Combination With Standard Chemotherapy for Squamous Cell Lung Carcinoma","status":"UNKNOWN","sponsor":"Swami Rama Cancer Hospital and Research Institute","startDate":"2013-10","conditions":"Lung Cancer, Squamous Cell Carcinoma of the Lung, Locally Advanced and Metastatic Squamous Cell Carcinoma of the Lung","enrollment":60},{"nctId":"NCT01210131","phase":"NA","title":"Hypoxia-guided Radiotherapy With Cisplatin-etoposide in Stage I-III : Small Cell Lung Cancer(SCLC)","status":"WITHDRAWN","sponsor":"Maastricht Radiation Oncology","startDate":"2013-07","conditions":"Small Cell Lung Cancer (SCLC)","enrollment":""},{"nctId":"NCT00621361","phase":"PHASE1","title":"Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-02","conditions":"Lung Cancer","enrollment":62},{"nctId":"NCT00089453","phase":"PHASE1","title":"Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2003-09","conditions":"Multiple Myeloma","enrollment":10},{"nctId":"NCT00403403","phase":"PHASE2","title":"A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2007-03","conditions":"Small Cell Lung Cancer","enrollment":102},{"nctId":"NCT01211002","phase":"PHASE4","title":"Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin for Local Advanced Non-small Cell Lung Cancer (NSCLC)","status":"UNKNOWN","sponsor":"Simcere Pharmaceutical Co., Ltd","startDate":"2010-10","conditions":"Non-small Cell Lung Cancer","enrollment":170}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Control arm","Standard intravenous chemotherapy"],"phase":"phase_3","status":"active","brandName":"Intravenous Cisplatin & etoposide","genericName":"Intravenous Cisplatin & etoposide","companyName":"Swami Rama Cancer Hospital and Research Institute","companyId":"swami-rama-cancer-hospital-and-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cisplatin and etoposide are chemotherapy agents that work together to damage cancer cell DNA and prevent cell division, leading to cancer cell death. Used for Small cell lung cancer, Germ cell tumors, Lymphomas.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}